2011

  • Isidor B, Lindenbaum P, Pichon O, Bézieau S, Dina C, Jacquemont S, Martin-Coignard D, Thauvin-Robinet C, Le Merrer M, Mandel JL, David A, Faivre L, Cormier-Daire V, Redon R, Le Caignec C. Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat Genet. 2011 6;43:306-8.
  • Duheron V, Hess E, Duval M, Decossas M, Castaneda B, Klöpper JE, Amoasii L, Barbaroux JB, Williams IR, Yagita H, Penninger J, Choi Y, Lézot F, Groves R, Paus R, Mueller CG. Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc. Natl. Acad. Sci. USA  2011;108: 5342-7.
  • Battaglia S, Dumoucel S, Chesneau J, Heymann MF, Picarda G, Gouin F, Corradini N, Heymann D, Rédini F. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient .J Bone Miner Res. 2011;26:2439-51.
  • Rousseau J, Escriou V, Lamoureux F, Brion R, Chesneau J, Battaglia S, Amiaud J, Scherman D, Heymann D, Rédini F, Trichet V. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res. 2011;26:2452-62.
  • Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, de Muret A, Louis-Brennetot C, Aurias A, Coindre JM, Guillou L, Pedeutour F, Duval H, Collin  C, De Pinieux G. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011;24:624-37.
  • Isidor B, Le Merrer M, Exner GU, Pichon O, Thierry G, Guiochon-Mantel A, David A, Cormier-Daire V, Le Caignec C. Serpentine fibula-polycystic kidney syndrome caused by truncating mutations in NOTCH2. Hum Mutat. 2011;32:1239-42.
  • David E, Guihard P, Brounais B, Riet A, Charrier C, Battaglia S, Gouin F, Ponsolle S, Bot RL, Richards CD, Heymann D, Rédini F, Blanchard F. Direct anti-cancer effect of oncostatin M on chondrosarcoma. Int J Cancer. 2011; 15;128:1822-3.
  • Lavenus S, Berreur M, Trichet V, Pilet P, Louarn P, Louarn G, Layrolle P. Adhesion and osteogenic differentiation of human mesenchymal stem cells on titanium nanopores. Eur Cell Mater. 2011;22:84-96.
  • Verdegaal SH, Bovée JV, Pansuriya TC, Grimer RJ, Ozger H, Jutte PC, San Julian M, Biau DJ, van der Geest IC, Leithner A, Streitbürger A, Klenke FM, Gouin FG, Campanacci DA, Marec-Berard P, Hogendoorn PC, Brand R, Taminiau AH. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients.Oncologist.2011;16:1771-9.
  • Verdegaal SH, Bovée JV, Pansuriya TC, Grimer RJ, Ozger H, Jutte PC, San Julian M, Biau DJ, van der Geest IC, Leithner A, Streitbürger A, Klenke FM, Gouin FG, Campanacci DA, Marec-Berard P, Luyten FP. Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology. J Cell Mol Med. 2011;15:1266-86.
  • Barnes J, Lim JM, Godard A, Blanchard F, Wells L, Steet R. Extensive mannose phosphorylation on Leukemia Inhibitory Factor (LIF) controls its extracellular levels by multiple mechanisms. J Biol Chem. 2011; 286:24855-64.
  • Cordonnier T, Langonné A, Sohier J, Layrolle P, Rosset P, Sensébé L, Deschaseaux F. Consistent osteoblastic differentiation of human mesenchymal stem cells with bone morphogenetic protein 4 and low serum. Tissue Eng Part C Methods. 2011;17:249-59.
  • Gómez-Barrena E, Rosset P, Müller I, Giordano R, Bunu C, Layrolle P, Konttinen YT, Luyten FP. Bone regeneration stem cell therapies and clinical studies in orthopaedics and traumatology. J Cell Mol Med 2011. 15:1266-86.
  • Herisson F, Heymann MF, Chétiveaux M, Charrier C, Battaglia S, Pilet P, Rouillon T, Krempf M, Lemarchand P, Heymann D, Gouëffic Y. Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis. 2011;216:348-54.
  • Baud'Huin M, Ruiz-Velasco C, Jego G, Charrier C, Gasiunas N, Gallagher J, Maillasson M, Naggi A, Padrines M, Rédini F, Duplomb L, Heymann D. Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Eur J Cell Biol.2011;90:49-57.
  • Lambert F, Léonard A, Drion P, Sourice S, Layrolle P, Rompen E. Influence of space-filling materials in subantral bone augmentation: blood clot vs. autogenous bone chips vs. bovine hydroxyapatite. Clin Oral Implants Res. 2011;22:538-45
  • Castaneda B, Simon Y, Jacques J, Hess E, Choi YW, Blin-Wakkach C, Mueller C, Berdal A, Lézot F. Bone resorption control of tooth eruption and root morphogenesis: Involvement of the receptor activator of NF-kB (RANK). J CellPhysiol. 2011; 226:74-85.
  • Rossignol J, Boyer C, Leveque X, Fink KD, Thinard R, Blanchard F, Dunbar GL, Lescaudron L. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: Morphological and behavioral outcomes. Behav Brain Res.2011; 217:369-78.
  • Azéma L, Davaine JM, Guyomarch B, Chaillou P, Costargent A, Patra P, Gouëffic Y. Endovascular repair of common femoral artery and concomitant arterial lesions. Eur J Vasc Endovasc Surg. 2011; 41:787-93.
  • Bourdeaut F, Isidor B, Ferrand S, Thomas C, Moreau A, Leclair MD, David A, Pierron G, Le Caignec C, Delattre O. Homozygous PTEN deletion in neuroblastoma arising in a child with Cowden syndrome. Am J Med Genet A. 2011;155A:1763-6.
  • Shimojima K, Isidor B, Le Caignec C, Kondo A, Sakata S, Ohno K, Yamamoto T. A new microdeletion syndrome of 5q31.3 characterized by severe developmental delays, distinctive facial features, and delayed myelination. Am J Med Genet A. 2011;155A:732-6.
  • Isidor B, Barbarot S, Bénéteau C, Le Caignec C, David A. Multiple capillary skin malformations, epilepsy, microcephaly, mental retardation, hypoplasia of the distal phalanges: report of a new case and further delineation of a new syndrome. Am J Med Genet A. 2011;155A:1458-60.
  • Berdal A, Castaneda B, Aïoub M, Nefussi JR, Mueller C, Descroix V, Lézot F. Osteoclasts in the dental micro environment:a delicate balance controls dental histogenesis. Cells Tissues Organs.2011;194:238-43.
  • Stretbuerger A, Henrichs M, Ahrens H, Lanvers-Kaminzky C, Gouin F, Gosheger G, Hardes J. Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78. Int Orthop. 2011;35:1369-73.
  • Gomez-Brouchet A, Bouvier C, Decouvelaere AV, Larousserie F, Aubert S, Leroy X, Guinebretière JM, Coulomb A, Cassagnau E, de Muret A, Audard V, Marie B, De Pinieux G. Place of the pathologist in the management of primary bone tumours (osteosarcoma and Ewing's family tumours after neo adjuvant treatment). Ann Pathol. 2011; 31:455-65.
  • Peyrode C, Gouin F, Vidal A, Auzeloux P, Besse S, Dauplat MM, Askienazy S, Heymann D, Chezal JM, Rédini F, Miot-Noirault E. A"Proteoglycan targeting strategy" for the scintigraphic imaging and monitoring of the swarm rat chondrosarcoma orthotopic model. Sarcoma. 2011; 691608
  • Carpentier B, Layrolle P, Legallais C. Bioreactors for bone tissue engineering. Int J Artif Organs.2011;34:259-70. Review.
  • Le Goff B, Heymann D. Pharmacodynamics of bisphosphonates in arthritis. Expert Rev Clin Pharmacol. 2011;4:633-41 review
  • David E, Blanchard F, Heymann MF, De Pinieux G, Gouin F, Rédini F, Heymann D. The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets. Sarcoma. 2011;932451 review

2010

  • Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Tumor bone microenvironment regulates osteoprotegerin anti- or pro-tumoral activity depending on the local receptor activator of nuclear factor kB ligand/TNF related apoptosis inducing ligand balance and the presence of proteoglycans. Biochimica Biophysica Acta Rev on Cancer, 2010, 1805: 17-24.
  • Le Goff B, Soltner E, Maugars Y, Rédini F, Heymann D, Berthelot JM. Association of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loos in a rat model of collagen induced arthritis. Arthritis Res Ther, 2010, R185, 1-10.
  • Lézot F, Blin-Wakkach C, Thomas B, Castaneda B, Bolanos A, Hotton D, Sharpe P, Heymann D, Carles G, Gregoriadis A, Berdal A. Dlx homeobox gene expression in osteoclasts. J Cell Physiol, 2010, 223: 779-787.
  • Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, Gouin F, Duplomb L, Heymann D. Interleukin-34 is expressed by giant cell tumour of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol, 2010, 221: 77-86.
  • Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F. Preclinical evidence of using TRAIL in Ewing's sarcoma therapy: TRAIL inhibits tumor growth, prevents osteolysis and increases animal survival. Clin Cancer Res, 2010,16: 2363-2374.
  • Philippeau JM, Durand JM, Carret JP, Leclercq S, Waast D, Gouin F. Dual mobility design use in preventing total hip replacement dislocation following tumor resection. Rev de chirurgie orthopedique et traumatologique. 2010, 96: 2-9. 
  • Uçkay I, Dinh A, Vauthey L, Asseray N, Passuti N, Rottman M, Biziragusenyuka J, Riché A, Rohner P, Wendling D, Mammou S, Stern R, Hoffmeyer P, Bernard L. Spondylodiscitis due to Propionibacterium acnes: report of twenty-nine cases and a review of the literature. Clin Microbiol Infect. 2010, 16: 353-358
  • Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010, 69:400-408. 
  • Rousseau J, Escriou V, Parrot P, Picarda G, Charrier C, Scherman D, Heymann D, Rédini F, Trichet V. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther, 2010, 17 : 387-397.
  • Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 2010, 77:201-215. 
  • Verron E, Masson M, Khoshniat S, Duplomb L, Wittrant Y, Baud'huin M, Badran Z, Bujoli B, Janvier P, Scimeca JC, Bouler JM, Guicheux J. Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts. Br J Pharmacol 2010, 159:1681-1692.
  • Perrot P, Rousseau J, Bouffaut A-L, Rédini F, Cassagnau E, Deschaseaux F, Heymann M-F, Heymann D, Duteille F, Trichet V, Gouin F. Safety concern between autologous fat graft, mesenchymal stem cells and osteosarcoma relapse. Plos One, 2010, 5, e10999: 1-10.
  • Asseray N, Papin C, Touchais S, Bemer P, Lambert C, Boutoille D, Tequi B, Gouin F, Raffi F, Passuti N, Potel G. Improving diagnostic criteria for Propionibacterium acnes osteomyelitis: A retrospective analysis. Scandinavian J Infect Dis 2010, 42: 421-425. 
  • Ruiz Velasco C., Colliec-Jouault S., Redini F, Heymann D., Padrines M.  Proteoglycans on bone tumor development. Drug Discov Today, 2010, 15: 553-560.
  • Isidor B, Pichon O, Redon R, Day-Salvatore D, Hamel A, A. Siwicka K, Bitner-Glindzicz M, Heymann D, Kjellén L, Kraus C, G. Leroy J, Mortier GR, Rauch A, Verloes A,  David A, Le Caignec C. Mesomelia-synostoses syndrome results from deletion of SULF1 and SLCO5A1 genes at 8q13. Am J Human Genetic, 2010, 87: 95-100.
  • Baraut J, Farge D, Jean-Louis F, Kesmandt H, Durant C, Verrecchia F, Michel L. Cytokines in systemic sclerosis. Pathol Biol (Paris), 
  • Odri G, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Rédini F. Zoledronic acid as new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res, 
  • Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D. Therapeutic approach of primary bone tumors by bisphosphonates. Current Pharm Des,
  • Baud'huin M, Ruiz-Velasco C, Jego G, Charrier C, Gasiunas N, Gallagher J, Maillasson M, Naggi A, Padrines M, Redini F, Duplomb L, Heymann D. Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors : role in osteoclastogenesis and bone resorption. Eur J Cell Biol

2009

  • Mori K, Ando K, Heymann D, Redini F. Receptor activator of nuclear factor-kappa Bligand (RANKL) stimulates bone-associated tumours through functional RANKexpressed on bone associated cancer cells? Histol Histopathol, 2009, 24: 235-242.
  • Lamoureux F, Picarda G, Garrigue L, Baud'huin M, Trichet V, Vidal A, Miot-Noirault E, Pitard B, Heymann D, Redini F. Glycosaminoglycans as potential regulators ofosteoprotegerin therapeutic activity in osteosarcoma. Cancer Res, 2009, 69: 526-536.
  • Lacreusette A, Barbieux I, Nguyen JM, Pandolfino MC, Dréno B, Jacques Y, Godard A, Blanchard F. Defective activations of STAT3 Ser727 and PKC isoforms lead to Oncostatin M resistance in metastatic melanoma cells. J Pathol, 2009, 217: 665-676.
  • Georges S, Ruiz Velasco C, Trichet V, Fortun Y, Heymann D, Padrines M.  Proteases and bone remodelling. Cytokine Growth FactorRev, 2009, 20:29-41
  • Blanchard F, Duplomb L, Baud'huin M, Brounais B. The dual role of IL6-type cytokines on bone remodelling and bone tumors. Cytokine Growth Factor Rev, 2009, 20:19-28.
  • Brounais B, David E, Chipoy C, Trichet V, Ferre V, Charrier C, Duplomb L, Berreur M, Rédini F, Heymann D, Blanchard F. Long term on costatin M treatment induces anosteocyte-like differentiation on osteosarcoma and calvaria cells. Bone, 2009, 44:830-839.
  • KwanTat S, Pelletier JP, Ruiz-Velasco C, Padrines M, Martel-Pelletier J.  Newperspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med, 2009,58: 29-40
  • Miot-Noirault E, Gouin F, Vidal A, Rapp M, Maublant J, Askienazy S, Chezal JM, Heymann D, Redini F, Moins N. First preclinical imaging of primary cartilage neoplasm andits local recurrence using 99Tc-NTP 15-5 radiotracer. J Nuclear Med, 2009, 50:1541-1547.
  •  Rossignol J, Boyer C, Thinard R, Remy S, Dugast AS, Dubayle D, Dey ND, Boeffard F, DelecrinJ, Heymann D, Vandhove B, Anegon I, Naveilhan P, Dunbar GL, Lescaudron L. Mesenchymalstem cells induce a weak immune response in the rat striatum after allo orxenotransplantation. J Cell Mol Med, 2009, 13:2547-58.
  • Dechaseaux F, Sensébé L, Heymann D. Mechanisms of bone repair and regeneration. Trends Mol. Med., 2009, 15:417-29.